November 15, 2023
PhRMA Chair Vas Narasimhan With Japan’s drug spending going too heavily towards off-patent branded medicines, it is time for the country to cut those costs and redirect the resources saved to better reward innovation, urges Vas Narasimhan, chair of the...read more